{"id":23455,"date":"2022-12-21T20:54:00","date_gmt":"2022-12-21T12:54:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23455"},"modified":"2025-01-27T20:58:05","modified_gmt":"2025-01-27T12:58:05","slug":"jw-therapeutics-collaborates-with-juno-for-dll3-car-t-therapy-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23455","title":{"rendered":"JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China-based JW Therapeutics Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/2126:HKG\">HKG: 2126<\/a>) has issued a stock exchange announcement revealing a strategic collaboration with its major shareholder Juno. The deal sees Juno grant licenses to patents and know-how in order to develop, manufacture, and commercialize a chimeric antigen receptor (CAR) T cell therapy targeting the solid tumor antigen DLL3 in the territory of Greater China.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Deal Details and Rights<\/strong><br>The deal covers exclusive rights to the development of a DLL3 CAR-T construct produced by Juno, and non-exclusive rights to related Juno diagnostics in support of that therapy. Juno has the option to take up co-commercialization rights in China for the resulting product, which would require a milestone payment of up to USD 50 million to JW. If that option is not exercised, JW will be required to pay reimbursements and milestone payments of up to USD 35 million to Juno in order to retain rights to the product, and will also pay royalties on future net sales. The deal still requires approval from shareholders.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Company Background and DLL3 Construct<\/strong><br>JW was established in 2016 as a joint venture between Juno Therapeutics \u2013 later acquired by Celgene and now part of Bristol-Myers Squibb \u2013 and China-based CRO WuXi AppTec Co., Ltd. Juno retains a 17.09% equity holding in JW. The DLL3 construct produced by Juno is described as a pre-clinical candidate that has already produced promising data indicating low toxicity and a strong tumor-killing ability even at lower levels of target expression. Delta-like canonical Notch ligand 3 (DLL3) belongs to the Notch receptor ligand family and is involved in Notch signaling. DLL3 is highly expressed in various lung cancers and neuroendocrine tumors, but rarely in normal tissues.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Future Prospects and Strategic Implications<\/strong><br>This strategic partnership positions JW Therapeutics to advance the development of innovative CAR-T therapies targeting solid tumors, leveraging Juno&#8217;s expertise and intellectual property. By focusing on the DLL3 antigen, JW aims to address significant unmet medical needs in oncology and improve patient outcomes through targeted immunotherapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[16,21,1165,321],"class_list":["post-23455","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-car-t","tag-hkg-2126","tag-jw-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a strategic collaboration with its major shareholder Juno. The deal sees Juno grant licenses to patents and know-how in order to develop, manufacture, and commercialize a chimeric antigen receptor (CAR) T cell therapy targeting the solid tumor antigen DLL3 in the territory of Greater China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23455\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23455\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-21T12:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-27T12:58:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23455#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23455\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development\",\"datePublished\":\"2022-12-21T12:54:00+00:00\",\"dateModified\":\"2025-01-27T12:58:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23455\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"CAR-T\",\"HKG: 2126\",\"JW Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23455#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23455\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23455\",\"name\":\"JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-21T12:54:00+00:00\",\"dateModified\":\"2025-01-27T12:58:05+00:00\",\"description\":\"China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a strategic collaboration with its major shareholder Juno. The deal sees Juno grant licenses to patents and know-how in order to develop, manufacture, and commercialize a chimeric antigen receptor (CAR) T cell therapy targeting the solid tumor antigen DLL3 in the territory of Greater China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23455#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23455\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23455#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development - Insight, China&#039;s Pharmaceutical Industry","description":"China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a strategic collaboration with its major shareholder Juno. The deal sees Juno grant licenses to patents and know-how in order to develop, manufacture, and commercialize a chimeric antigen receptor (CAR) T cell therapy targeting the solid tumor antigen DLL3 in the territory of Greater China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23455","og_locale":"en_US","og_type":"article","og_title":"JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23455","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-21T12:54:00+00:00","article_modified_time":"2025-01-27T12:58:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23455#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23455"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development","datePublished":"2022-12-21T12:54:00+00:00","dateModified":"2025-01-27T12:58:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23455"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","CAR-T","HKG: 2126","JW Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23455#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23455","url":"https:\/\/flcube.com\/?p=23455","name":"JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-21T12:54:00+00:00","dateModified":"2025-01-27T12:58:05+00:00","description":"China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a strategic collaboration with its major shareholder Juno. The deal sees Juno grant licenses to patents and know-how in order to develop, manufacture, and commercialize a chimeric antigen receptor (CAR) T cell therapy targeting the solid tumor antigen DLL3 in the territory of Greater China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23455#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23455"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23455#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23455"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23455\/revisions"}],"predecessor-version":[{"id":23456,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23455\/revisions\/23456"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}